Citius Oncology Drives LYMPHIR Adoption in Cancer Care
CRANFORD, N.J., March 31, 2026 Citius Oncology, Inc. has reported strong early momentum following the U.S. launch of its...
Cancer Immunotherapy
Advertisement
OS Therapies Advances OST-HER2 Toward FDA Approval
NEW YORK, March 31, 2026 — OS Therapies, Inc a clinical-stage oncology company specializing in listeria-based cancer immunotherapies, has...
CStone CS2009 Shows Strong Phase I/II Cancer Data
Suzhou, China – March 26, 2026 CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong...
Incyte’s Zynyz Approved in EU for Advanced Anal Cancer
March 06, 2026 — Wilmington, Delaware, USA Global biopharmaceutical innovator Incyte has announced that the European Commission has approved...
Johnson & Johnson Wins FDA Approval for Tecvayli–Darzalex Myeloma Therapy
HORSHAM, Pennsylvania – March 5, 2026 Johnson & Johnson announced that the U.S. Food and Drug Administration has approved...
Advertisements
FDA Clears Scancell IND for Phase 3 iSCIB1+ Melanoma Trial
Cambridge, United Kingdom, January 26, 2026 — Scancell Holdings plc announced on January 26, 2026, that the U.S. Food...
SELLAS Updates Phase 3 REGAL Trial in AML
NEW YORK, December 29, 2025 — SELLAS Life Sciences Group has provided a key update on its pivotal Phase...
CancerVax Marks 2025 Breakthroughs in Cancer Immunotherapy
LEHI, Utah — December 23, 2025 — CancerVax, a pre-clinical biopharmaceutical innovator, has released a year-end scientific and strategic...
Greenwich Reports 80% Recurrence Reduction in FLAMINGO-01
STAFFORD, Texas — December 15, 2025 — Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, announced a preliminary analysis from...
Phio Pharmaceuticals Advances siRNA Immunotherapy in Skin Cancer with INTASYL PH-762
Dateline — King of Prussia, Pennsylvania, November 7, 2025:Phio Pharmaceuticals Corp. (NASDAQ: PHIO) has announced new clinical data from...
Advertisement
